Eli Lilly Reaches $1 Trillion Valuation on Weight-Loss Drug Boom
Eli Lilly has made history by becoming the first pharmaceutical company to reach a $1 trillion market valuation, driven by surging demand for its weight-loss medications.
Key Milestone Achieved
The American pharmaceutical giant reached this historic milestone when its shares climbed 2% to over $1,060 during Wall Street trading. This achievement places Eli Lilly among an elite group of trillion-dollar companies including tech giants Nvidia, Microsoft, and Apple, alongside Elon Musk’s Tesla and Warren Buffett’s Berkshire Hathaway.
Strong Market Performance
Eli Lilly’s stock has demonstrated remarkable growth, jumping 47% over the past six months. This represents a significant recovery from August’s setback when trial data for its experimental weight-loss pill orforglipron failed to meet expectations.
Outpacing Competition
The company has successfully pulled ahead of its main competitor, Danish firm Novo Nordisk, which manufactures rival weight-loss drugs Wegovy and Ozempic. Recent financial results show Eli Lilly’s impressive performance, with revenues surging 54% to £13.4 billion in the three months to September. This stands in stark contrast to Novo Nordisk’s stock, which has declined by 52% so far this year.
Positive Market Outlook
Investor confidence has been further strengthened by the receding threat of pharmaceutical import tariffs that had been proposed by US President Donald Trump, creating a more favorable market environment for the company’s continued growth.
